Head and Neck Sarcomas: A Comprehensive Cancer Center Experience

Cancers

Mohamedtaki A. Tejani¹  Thomas J. Galloway³  Miriam Lango²  John A. Ridge² 

[1] Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA; E-Mail:;Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA; E-Mails:;Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA; E-Mail:

关键词: head and neck sarcomas;    soft tissue sarcomas;    osteogenic sarcomas;   

DOI  :  10.3390/cancers5030890

来源: mdpi

【 摘 要 】

Head/neck sarcomas are rare, accounting for about 1% of head/neck malignancies and 5% of sarcomas. Outcomes have historically been worse in this group, due to anatomic constraints leading to difficulty in completely excising tumors, with high rates of local recurrence. We retrospectively analyzed cases of head/neck soft tissue sarcomas (STS) and osteogenic sarcomas managed in a multi-disciplinary setting at Fox Chase Cancer Center from 1999–2009 to describe clinicopathologic characteristics, treatment, outcomes, and prognostic factors for disease control and survival. Thirty patients with STS and seven patients with osteogenic sarcoma were identified. Most STS were high grade (23) and almost all were localized at presentation (28). Common histologies were synovial cell (6), rhabdomyosarcoma (5), angiosarcoma (4), liposarcoma (4) and leiomyosarcoma (3). The type of primary therapy and disease outcomes were analyzed. Cox proportional hazards regression analysis was performed to identify predictors of disease-free survival (DFS) and overall survival (OS). The HR and 95% CI for Cox model and median DFS/OS analyzed by Kaplan-Meier curves were calculated.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.